Business, energy, technology, markets and global industry news from Business News Today

Spevigo

PharmaDeviceNews Spevigo
LEO Pharma’s 10% CER revenue growth, led by expanding dermatology brands including Anzupgo and Spevigo, comes as the company increases investment in its late-stage pipeline and rare skin disease portfolio. Representative image.
Pharma & Biotech

LEO Pharma’s sales engine is accelerating, but its next growth bet is already squeezing margins

LEO Pharma’s strategic brands are surging as dersimelagon expands its pipeline, but heavier investment is putting 2026 margins under pressure.

Read More
Vanda Pharmaceuticals advances imsidolimab for generalized pustular psoriasis after a positive European Medicines Agency orphan drug recommendation, although approval and commercialisation hurdles remain. Representative image.
Pharma & Biotech

Vanda’s imsidolimab has won a rare European advantage, but one approved rival changes the equation

Vanda’s imsidolimab gains an EMA orphan recommendation for GPP, but approval, differentiation and European access remain ahead.

Read More